In patients with multiple myeloma, the disease is often refractory to first-line triple or quadruple therapies. The result: a relapse occurs. Therefore, effective second-line therapy combinations are needed that include new treatment approaches.
Autoren
- Birke Dikken
Publikation
- InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
You May Also Like
- New evidence on genetics, pathophysiology and clinical significance
Migraine with and without aura – two different entities?
- Prevention of skin cancer
UV protection and skin cancer screening – Update 2025
- Case report: L. pneumophila pneumonia
Negative test results – but no alternative diagnoses
- Clinical case reports and implications for GP care
Magnesium deficiency and dilated cardiomyopathy in the peripartum context
- SID Annual Meeting: Highlights
Update on inflammatory dermatoses – a concentrated load of innovative power
- Case series
Bleeding prophylaxis for von Willebrand disease
- A critical analysis of the evidence from 113 studies
Nutrition and depression
- An emerging interface with clinical relevance